Back to Search Start Over

The optimal imaging window for dysplastic colorectal polyp detection using c-met-targeted fluorescence molecular endoscopy

Authors :
Marieke L. de Kam
Arend Karrenbeld
Jessie Westerhof
Iris Schmidt
Jan J. Koornstra
Ingrid M C Kamerling
Wouter B. Nagengast
F. J. Voskuil
James C. H. Hardwick
Steven J de Jongh
Dominic J. Robinson
Josephina P.M. Vrouwe
Jacobus Burggraaf
Otorhinolaryngology and Head and Neck Surgery
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Source :
Journal of Nuclear Medicine, 61(10), 1435-1441. SOC NUCLEAR MEDICINE INC, Journal of Nuclear Medicine, 61(10), 1435-1441. Society of Nuclear Medicine and Molecular Imaging
Publication Year :
2020

Abstract

Fluorescence molecular endoscopy (FME) is an emerging technique that has the potential to improve the 22% colorectal polyp detection miss-rate. We determined the optimal dose-to-imaging interval and safety of FME using EMI-137, a c-Met-targeted fluorescent peptide, in a population at high risk for colorectal cancer. Methods: We performed in vivo FME and quantification of fluorescence by multidiameter single-fiber reflectance/single-fiber fluorescence spectroscopy in 15 patients with a dysplastic colorectal adenoma. EMI-137 was intravenously administered (0.13 mg/kg) at a 1-, 2- or 3-h dose-to-imaging interval (n = 3 patients per cohort). Two cohorts were expanded to 6 patients on the basis of target-to-background ratios. Fluorescence was correlated to histopathology and c-Met expression. EMI-137 binding specificity was assessed by fluorescence microscopy and in vitro experiments. Results: FME using EMI-137 appeared to be safe and well tolerated. All dose-to-imaging intervals showed significantly higher fluorescence in the colorectal lesions than in surrounding tissue, with a target-to-background ratio of 1.53, 1.66, and 1.74 for the 1-, 2-, and 3-h cohorts, respectively, and a mean intrinsic fluorescence of 0.035 vs. 0.023 mm-1 (P < 0.0003), 0.034 vs. 0.021 mm-1 (P < 0.0001), and 0.033 vs. 0.019 mm-1 (P < 0.0001), respectively. Fluorescence correlated with histopathology on a macroscopic and microscopic level, with significant c-Met overexpression in dysplastic mucosa. In vitro, a dose-dependent specific binding was confirmed. Conclusion: FME using EMI-137 appeared to be safe and feasible within a 1- to 3-h dose-to-imaging interval. No clinically significant differences were observed among the cohorts, although a 1-h dose-to-imaging interval was preferred from a clinical perspective. Future studies will investigate EMI-137 for improved colorectal polyp detection during screening colonoscopies.

Details

Language :
English
ISSN :
01615505
Database :
OpenAIRE
Journal :
Journal of Nuclear Medicine, 61(10), 1435-1441. SOC NUCLEAR MEDICINE INC, Journal of Nuclear Medicine, 61(10), 1435-1441. Society of Nuclear Medicine and Molecular Imaging
Accession number :
edsair.doi.dedup.....c611f0f8192fd3ae64d20e23297406e9